Journal article

Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy

Robert N Doughty, GA Whalley, GD Gamble, J Baker, J Chalmers, M Cooper, K Cruickshank, P Dixon, P Dunne, D Eccleston, G Jerums, R Luke, B McGrath, C Nolan, A Patel, N Poulter, P Phillips, R Scott, J Singh, R Smith Show all

Journal of Hypertension | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011

Abstract

BACKGROUND: The Action in Diabetes and Vascular Disease (ADVANCE) Study demonstrated that a fixed combination of perindopril and indapamide reduced the risk of major vascular events and mortality in patients with type 2 diabetes. This Echocardiographic Substudy was designed to determine the effects of this treatment on left ventricular diastolic function and left ventricular mass. METHODS: Five hundred and fifty-five patients entering ADVANCE underwent quantitative echocardiography prior to randomization and after 6 months and 4 years of treatment with perindopril-indapamide or placebo. Main end points were left ventricular diastolic function (ratio of mitral E velocity/early medial mitral a..

View full abstract

Grants

Funding Acknowledgements

The ADVANCE Echocardiography substudy was funded by grants from the George Institute for International Health University of Sydney, the Institut de Recherches Internationales Servier, the New Zealand National Heart Foundation and the AH Couch Trust, New Zealand.A. Patel reports receiving lecture fees from Servier, Pfizer and Abbott and grant support from Pfizer, Servier and Sanofi-Aventis.S. MacMahon, being a member of advisory boards for Servier, Pfizer and Novartis, reports receiving lecture fees from Servier and Pfizer and research grants from Servier, Pfizer and Novartis.J. Chalmers, being a member of an advisory board for Servier, receives lecture fees from Servier, Pfizer and Daiichi and grant support from Servier.B. Neal receives lecture fees from Servier and GlaxoSmithKline and research grants from Pfizer.M. Cooper receives consulting fees from Merck, GlaxoSmithKline, Amgen and Astra-Zeneca and lecture fees from Servier.P. Hamet receives consulting fees from Servier, Neurochem, Prognomix, Medpharmgene, Novartis, Bristol-MyersSquibb, Pfizer and Boehringer Ingelheim; lecture fees from Servier, Novartis, Pfizer and Bristol-Myers Squibb; and grant support from Pfizer.S. Heller receives consulting fees from Novo Nordisk, Eli Lilly and Amylin; lecture fees from Novo Nordisk, Eli Lilly, Servier and Merck; and grant support from Novo Nordisk and GW Pharmaceuticals.G. Mancia receives consulting and lecture fees from Servier, Novartis, Bayer, Boehringer Ingelheim, Merck and Sanofi-Aventis.N. Poulter receives consulting fees from Gilead, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sankyo, Merck, Preventicum and Pfizer; lecture fees from Servier, Novartis, Pfizer, Bristol-Myers Squibb and Sanofi-Aventis; and grant support from Servier, Pfizer, Mars and Menarini.A. Rodgers receives lecture fees from Pfizer and Merck and grant support from Dr Reddy's Laboratories.